Exenatide
- Generic Name
- Exenatide
- Brand Names
- Bydureon, Byetta
- Drug Type
- Biotech
- CAS Number
- 141758-74-9
- Unique Ingredient Identifier
- 9P1872D4OL
- Background
Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations. Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.
- Indication
Exenatide is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. An extended-release formulation is available which is indicated in patients ≥10 years old, while the immediate-acting formulation is approved only for adult patients.
- Associated Conditions
- Type 2 Diabetes Mellitus
Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2019-06-20
- Lead Sponsor
- Emory University
- Target Recruit Count
- 150
- Registration Number
- NCT02455076
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸Grady Memorial Hospital, Atlanta, Georgia, United States
Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT02449603
- Locations
- 🇨🇳
Xijing Hospital, Fourth Military Medical university, Xi'an, Shaanxi, China
GLP-1 Analogs for Neuroprotection After Cardiac Arrest
- Conditions
- ComaCardiac Arrest
- Interventions
- Other: 20% Human Albumin
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2017-09-28
- Lead Sponsor
- Jesper Kjaergaard
- Target Recruit Count
- 120
- Registration Number
- NCT02442791
- Locations
- 🇩🇰
Kardiologisk Afdeling, Rigshospitalet, Copenhagen, Denmark
Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 64
- Registration Number
- NCT02432976
- Locations
- 🇫🇷
Post operative intensive care unit of the cardiac surgery department, Besançon, France
Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia
- Conditions
- Schizoaffective DisorderSchizophrenia
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-04-15
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- University of Massachusetts, Worcester
- Target Recruit Count
- 70
- Registration Number
- NCT02417142
- Locations
- 🇺🇸
UMass Medical School, Worcester, Massachusetts, United States
COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial
- Conditions
- ST Elevation Acute Myocardial Infarction
- Interventions
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2020-11-03
- Target Recruit Count
- 378
- Registration Number
- NCT02404376
- Locations
- 🇪🇸
Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
🇪🇸Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital Universitario Valle de Hebron, Barcelona, Spain
Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- University of Palermo
- Target Recruit Count
- 60
- Registration Number
- NCT02380521
- Locations
- 🇮🇹
University Hospital of Palermo, Palermo, Italy
Efficacy and Mechanism of Exenatide on Improving Heart Function in Type 2 Diabetes With Heart Failure Patients
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Target Recruit Count
- 234
- Registration Number
- NCT02344641
A Comparison of Exenatide and Insulin Glargine
- First Posted Date
- 2014-12-25
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Target Recruit Count
- 44
- Registration Number
- NCT02325960
- Locations
- 🇨🇳
at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University, Nanjing, Jiangsu, China
Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- Uppsala University
- Target Recruit Count
- 50
- Registration Number
- NCT02313220
- Locations
- 🇸🇪
Dept of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University and Section for Diabetes and Endocrinology at the Uppsala University Hospital, Uppsala, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.